REDWOOD CITY, Calif.,
April 14, 2015 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced
that a poster presentation will be made at the Annual Society of
American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting
to be held April 15th to
April 18th, 2015 at the
Gaylord Opryland Resort and Convention Center in Nashville, TN. SAGES 2015 will continue a
long-standing tradition of strong didactic sessions by
world-renowned experts, combined with exploration of innovative
technology. The meeting will bring together Gastrointestinal and
Endoscopic surgeons representing over 70 different
countries.
The presentation includes results from the previously announced
phase 3 results of Zalviso in abdominal patients and the phase 2
results of ARX-04 bunionectomy trial. Both studies were
multi-center, randomized, double-blind and placebo-controlled.
Details on the presentation time are as follows:
|
Thursday, April 16,
2015 – Emerging Technology Poster Session located in the Exhibit
Hall - Presentation time 9:00am-4:00pm (local time).
|
|
|
Authors:
|
Neil Singla, MD;
Harold Minkowitz, MD; Tong-Joo Gan, MD; Yu-kun Chiang, PhD;
Karen DiDonato, MSN, RN; Pamela Palmer, MD, PhD
|
|
|
|
Title:
|
SUBLINGUAL
SUFENTANIL FOR THE MANAGEMENT OF ACUTE PAIN
|
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for the treatment of acute and breakthrough
pain. AcelRx's lead product candidate, Zalviso, is designed
for the management of moderate-to-severe acute pain in adult
patients in the hospital setting by utilizing a high therapeutic
index opioid, through a non-invasive delivery route via a
pre-programmed, patient-controlled analgesia device. AcelRx has
announced positive results from each of the three completed Phase 3
clinical trials for Zalviso, and has submitted an NDA to the FDA
seeking approval for Zalviso in the treatment of moderate-to-severe
acute pain in adult patients in the hospital setting and on
July 25th, received a Complete
Response Letter from the FDA. AcelRx recently received
correspondence from the FDA stating that in addition to the bench
testing and two Human Factors studies AcelRx has performed, an
additional clinical study is needed to assess the risk of
inadvertent dispensing and overall risk of dispensing failures.
AcelRx plans to meet with the FDA to discuss and clarify the need
and potential objectives of an additional clinical study for
Zalviso. AcelRx has initiated a Phase 3 clinical trial for ARX-04,
a product candidate for the treatment of moderate-to-severe acute
pain in a medically supervised setting.
The Company has two additional pain treatment product
candidates, ARX-02 and ARX-03, which have completed Phase 2
clinical development. For additional information about AcelRx's
clinical programs, please visit www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-presentation-of-sublingual-sufentanil-data-at-the-society-of-american-gastrointestinal-and-endoscopic-surgeons-meeting-300065187.html
SOURCE AcelRx Pharmaceuticals, Inc.